Literature DB >> 17349560

Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis.

Miguel A Pena1, Murad Alam, Simon S Yoo.   

Abstract

In dermatology, botulinum toxin is now most often used to reduce dynamic facial creases and treat primary focal hyperhidrosis. The exemplary safety record of this medication is such that after nearly 2 decades, it is not known to have any long-term adverse events. Transient adverse events, such as mild injection pain, are typically minor and spontaneously remitting. Headache, nausea and flu-like symptoms, lid and brow ptosis after upper face injection, lower face asymmetry after perioral injection, and fine motor impairment after palmar injection are uncommon to rare. Understanding of anatomic landmarks and site-specific precautions can further mitigate the incidence of unwanted effects. Patients who do experience uncommon, transient effects can be reassured that these are not dangerous and will resolve completely without intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349560     DOI: 10.1016/j.sder.2006.12.004

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  4 in total

1.  Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminium chloride hexahydrate in treatment of palmar hyperhidrosis.

Authors:  R Rajagopal; Nikhitha B Mallya
Journal:  Med J Armed Forces India       Date:  2014-04-26

2.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

Review 3.  Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review.

Authors:  Joel L Cohen; Nicolo Scuderi
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

4.  Complications of minimally invasive cosmetic procedures: prevention and management.

Authors:  Lauren L Levy; Jason J Emer
Journal:  J Cutan Aesthet Surg       Date:  2012-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.